Using immunotherapy and chemotherapy for advanced gastric cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study evaluates the efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line and neoadjuvant therapy for patients with advanced gastric cancer. The study also aims to investigate relevant biomarkers to enhance understanding of immunotherapy outcomes. Eligible participants include those who have not received prior anti-tumor therapy and are expected to receive immunotherapy. The study is conducted at Qilu Hospital of Shandong University in Jinan, Shandong.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 years old or above
2. Patients with advanced gastric cancer or locally advanced gastric cancer
3. Have not received any previous anti-tumor therapy
4. Patients expected to receive immunotherapy for first-line or neoadjuvant therapy
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
6. Adequate organ function

Exclusion Criteria:

1. Patients with contraindications to immunotherapy
2. Have received anti-tumor treatments such as immunotherapy and chemotherapy
3. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases
4. Severe chronic or active infection requires systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection. Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment
5. History of allogeneic stem cell transplantation or organ transplantation

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Lian Liu, MD — Qilu Hospital of Shandong University
• Study coordinator: Lian Liu, MD
• Email: tounao@126.com
• Phone: 0531-82169851

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Immunotherapy Response in Advanced Gastric Cancer using PET Imaging

  This study tests whether FAPI PET/CT and Grazytracer PET/CT can predict how advanced gastric cancer will respond to preoperative immunotherapy-based treatment.

  Recruiting Ruijin Hospital · Shanghai · NCT07824479

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Low-leucine diet with chemotherapy and immunotherapy for advanced stomach cancer

  This will test whether a low-leucine diet helps people with advanced gastric cancer respond better to combined chemotherapy and immunotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07537348

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• QL1706 (Iparomlimab + Tuvonralimab) with SOX chemotherapy for untreated advanced or metastatic gastric or gastroesophageal junction cancer

  This trial will test whether adding QL1706 (two immunotherapy drugs) to SOX chemotherapy helps people with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer get a better tumor response.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07315854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.